Literature DB >> 6186237

Serologic evidence in commercial chicken and turkey flocks of infection with reticuloendotheliosis virus.

R L Witter, I L Peterson, E J Smith, D C Johnson.   

Abstract

A serologic survey has documented probable infection with reticuloendotheliosis (RE) virus in 21.0% of 101 layer flocks, 23.5% of 85 broiler and broiler-breeder flocks, 2.3% of 43 backyard chicken flocks, and 4.8% of 125 turkey production and breeder flocks. However, no infection was detected in 72 grandparent lines of chicken breeding stocks representing meat-type and layer strains. The existence of natural infection was further supported by isolation of RE virus from one experimental chicken flock and two commercial turkey flocks. This study supports earlier but subsequently discounted data by Aulisio and Shelokov that exposure to RE virus occurs commonly among commercial chickens in the United States, as has also been reported in other countries.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6186237

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  3 in total

1.  Serologic differences among nondefective reticuloendotheliosis viruses.

Authors:  P Y Chen; Z Cui; L F Lee; R L Witter
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  Co-Infection with Marek's Disease Virus and Reticuloendotheliosis Virus Increases Illness Severity and Reduces Marek's Disease Vaccine Efficacy.

Authors:  Guo-Rong Sun; Yan-Ping Zhang; Lin-Yi Zhou; Hong-Chao Lv; Feng Zhang; Kai Li; Yu-Long Gao; Xiao-Le Qi; Hong-Yu Cui; Yong-Qiang Wang; Li Gao; Qing Pan; Xiao-Mei Wang; Chang-Jun Liu
Journal:  Viruses       Date:  2017-06-21       Impact factor: 5.048

3.  Gut microbiota profiles of commercial laying hens infected with tumorigenic viruses.

Authors:  Xianhua Wan; Laipeng Xu; Xiangli Sun; Hui Li; Fengbin Yan; Ruili Han; Hong Li; Zhuanjian Li; Yadong Tian; Xiaojun Liu; Xiangtao Kang; Zhenya Wang; Yanbin Wang
Journal:  BMC Vet Res       Date:  2020-06-29       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.